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Abstract 
 
Since the introduction of calcium phosphate cements (CPCs) in 1985, a number of CPCs 
became predominantly commercially available for use in trauma and orthopaedic surgery. The 
aim of this technical note was to provide the relevant knowledge about CPCs that may 
improve the selection of CPCs for bone defects encountered in trauma and orthopaedic 
surgery. This includes a classification based on the chemical composition, and details about 
structural, mechanical and biological properties. Furthermore, the biological performance of 
each CPC was assessed in an animal study. And finally, a systematic literature search was 
conducted to provide a comprehensive overview of currently available clinical literature of 
these CPCs in trauma and orthopaedic surgery. 
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Introduction 
 
Halve of the population sustains at least one fracture during their lifetime1, and the majority of 
these fractures heal successfully. Successful fracture healing requires the following five 
elements; (i) osteogenic cells (e.g., osteoblasts), (ii) osteoinductive stimuli (e.g., bone 
morphogenetic proteins); (iii) an osteoconductive matrix; (iv) adequate blood and nutrient 
supply, and (v) sufficient mechanical support2. One or more elements can be compromised 
due to the existence of a bone defect. Bone defects are treated with bone grafts in order to 
avoid insufficient fracture healing. Insufficient fracture healing is encountered in 5 to 10% of 
the fractures, resulting in delayed union, malunion, or non-union3. 
Most commonly used bone graft material is autologous bone. Autologous bone is usually 
harvested from the iliac crest4. However, harvesting autologous bone lengthens the surgical 
procedure and is associated with complications in 8-39% of patients (e.g., infection, nerve and 
urethral injury, and postoperative or chronic pain)5. An alternative option is to use allogeneic 
bone. However, allogeneic bone grafting is considered suboptimal since it has 
biocompatibility disadvantages6. The disadvantages of autologous and allogeneic bone grafts 
have resulted in the development of alternative (synthetic) bone substitute materials. The most 
interesting group of bone substitute materials is probably calcium phosphate (CaP), because 
CaPs mimic the mineral part of natural bone7. 
CaP-based bone substitutes have been studied for several decades8 and they can be 
categorized into CaP ceramics and CaP cements (CPC)7. CaP ceramics are obtained by 
thermal treatment (sintering), generally resulting in solid grafting materials (e.g., blocks or 
granules). CPCs, on the other hand, consist of CaP powder that forms a paste upon mixing 
with a liquid. Mixing is usually done during surgery and the resulting paste becomes solid 
within several minutes through an isothermic chemical setting reaction. During this setting 
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reaction, the CPCs can be moulded by the surgeon into any desired shape in order to 
completely fill the defect.  
Since the introduction of CPC in 1985 by Brown and Chow, a number of CPCs have 
become commercially available for trauma and orthopaedic surgery9. Trauma or orthopaedic 
surgeons are therefore given the opportunity to select a CPC that meets the specific demands 
of each bone defect that requires bone grafting. The aim of this technical note was to provide 
a comprehensive overview of knowledge of commonly used CPCs that may improve this 
selection for bone defects encountered during fracture treatment. The chemical composition 
and structural, mechanical and biological properties of the four predominantly used CPC 
products (Table 1) are discussed. In addition, the biological properties were evaluated in a 
large animal bone defect model. Finally, a systematic literature search was conducted in order 
to provide insight into the available clinical evidence supporting to use of these CPC products 
to graft bone defects encountered during fracture treatment. 
 
Calcium phosphate cements 
CPCs can be classified based upon the setting product of the CPC into apatite-forming and 
brushite-forming CPCs. This classification refers to the degree of crystallinity of the CaP 
formed and has a direct impact on their resorption rate. The resorption of an apatite-forming 
CPCs is very limited and takes many years, whereas the resorption of brushite-forming CPCs 
takes place within several months7. Commercially available apatite-forming CPCs are 
BoneSource®, Calcibon®, and Norian SRS®, a brushite-forming CPC is ChronOSTM Inject 
(Table 2). CPC products are available in several quantities, ranging from 1.5 cc to 30 cc 
(Table 1), and depending on the CPC product the setting reaction will take five (Calcibon®) or 
fifteen minutes (Norian SRS®) to be completed once the components are mixed (Table 2). 
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It is necessary to distinguish CPCs from ceramic CaPs. The ceramic CaPs are acquired 
from heating (sintering) of calcium phosphate powder up to 800-1300 ºC. This heating results 
in formation of solid porous blocks or granules that can consist of hydroxyapatite (HA), 
tricalcium phosphate (TCP) or a combination HA and TCP (composites). Examples of 
commercially available CaP ceramics are BoneSave®, Camceram®, Cerabone®, ChronOSTM, 
Endobon®, Ostim®, Pro Osteon 500®, and Vitoss® 10. 
 
Structural properties 
CPCs are generally described as being osteoconductive11. Osteoconduction is defined as the 
ability of a graft material to function as a scaffold that allows ingrowth of bone and vascular 
tissues12. A scaffold that offers an open porous structure with pore dimensions of 150-500 μm 
is considered optimal for bone ingrowth12 . CPCs generally form dense structures with limited 
porosity (Table 3). In vitro micro-CT measurements indicate that the porosity of ChronOSTM 
Inject is only 5±1 %, and that the porosity of apatite-CPCs does not exceed 5 % 
(BoneSource® 0.4±0.3 %, Calcibon® 0.9±0.5 %, Norian SRS® 0.3±0.2 %)13. Furthermore the 
majority of these pores is smaller than 150 µm. Average pore size of ChronOSTM Inject is 100 
µm, and 18 % of these pores exceed the size of 150 µm. Average pore sizes of other apatite-
CPCs is ~50 µm and the fraction that exceeds the size of  150 µm is less than 4 %. 
 
Mechanical properties 
The mechanical properties of a bone substitute material should ideally be comparable to the 
bone being replaced. However, the mechanical properties of bone differ according to their 
structure (cortical or trabecular bone) and function (weight-bearing or non-weight-bearing). 
Compression strength of human cortical bone is in the range of 130 to 190 MPa, whereas 
trabecular bone has a compression strength of 8 to 38 MPa. Apatite-CPCs were found to have 
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a compression strength in the range of trabecular bone (Table 3); Calcibon® has the highest 
compression strength (34±7 MPa), followed by Norian SRS® (26±7 MPa) and BoneSource® 
(14±3 MPa). The brushite-CPC ChronOSTM Inject has a compression strength that is much 
lower and does not exceed values of 1 MPa13. 
 
Biological properties  
Biological properties of four CPCs were studied in a drill-hole tibia bone defect model in 
goats14. This model allows for a direct comparison of different CPCs. Three months after 
grafting the drill-hole defects with different CPCs, resorption and bone formation were 
determined using micro-CT scanning, histology, and fluorochrome labeling (Supplementary 
Materials and Methods). The study was approved by the institution’s Animal Ethics 
Committee (EUR1540). 
The micro-CT scans acquired at three months after grafting showed that drill-hole 
defects remained adequately filled by apatite-based CPCs (BoneSource®, Calcibon®, and 
Norian SRS®). This indicates limited resorption of apatite-CPCs whereas using ChronOSTM 
Inject resulted in a partially remaining bone defect (Figure 1); the latter is most likely the 
result of fast resorption of this brushite-CPC. Detailed views of defects with CPCs showed 
that it is difficult to distinguish CPC from native bone as the radiographic density is very 
close (BoneSource®, Norian SRS®) or even similar (Calcibon®, ChronOSTM Inject) to native 
bone. These similar radiographic densities obstruct a quantitative analysis from these micro-
CT images of newly formed bone and remaining CPC volumes. 
Histology confirmed that resorption rate of apatite-CPCs is very limited and that, as a 
result, these CPCs remained largely intact (Figure 2). Calcibon® still covered almost the 
complete defect and hardly any bone ingrowth had appeared within three months. 
Furthermore little activity of bone formation at the CPC-interface, indicated by the 
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fluorochrome labels, was found in defects grafted with Calcibon®. Although BoneSource® 
also covered the majority of the defect, some resorption did take place within the three 
months follow-up. The fact that BoneSource® resorbed slowly was also shown by Welch et 
al15. In their study, subchondral femoral bone defects in goats were grafted with 
BoneSource®, and 38 % of the CPC was still present after two years. A similar resorption 
pattern was also seen for Norian SRS®. Apelt et al. indicated that approximately 5 % of 
Norian SRS® was resorbed at six months after grafting a comparable subchondral bone defect 
in sheep16. The minimal appearance of fluorochrome labels at CPC-interface of tibia defects 
grafted with BoneSource® and Norian SRS®  also indicate little bone forming activity (Figure 
2). 
Histology of the only brushite-based CPC, ChronOSTM Inject, indicated indeed that 
most of CPC was resorbed within three months time. This was also shown by Apelt et al., 
who found that only 20 % of ChronOSTM Inject was still present six months after grafting 
subchondral bone defects in sheep16. In the periphery of the defect, ChronOSTM Inject had 
resorbed and was replaced by new bone. After three months, only some bits of CPC were 
found within the center of the defect (Figure 2). Contrary to the limited bone forming activity 
found for apatite-CPCs, this brushite-CPC seemed to elect a bone formation activity almost 
throughout the complete CPC-interface (Figure 2). 
 
Clinical evidence in fracture treatment 
A systematic literature search was conducted using the product names of all products (Table 
1) as search terms in PubMed database. PubMed database was searched from the earliest date 
available until October 26, 2012. The following filters were used: species (human), languages 
(Dutch, English, or German), search fields (Text word). Retrieved manuscripts were only 
included when they contained original research on CPC use in trauma and orthopaedic related 
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indications. Manuscripts were excluded when they only contained data describing in vitro 
(e.g. cellular response or cadaver studies) or animal experiments, or when the CPC was used 
in other than trauma and orthopaedic related indications (e.g. dental or craniofacial surgery). 
All references of included manuscripts were reviewed in order to ensure that no relevant 
papers had been missed. 
The systematic literature search resulted in seventy-eight eligible manuscripts. Thirty-
three of these manuscripts were selected for final inclusion, including one additional reference 
(Table 4). The included manuscripts consisted of ten clinical trials, two case-control studies, 
twenty case-series and one case-report. The four CPC have been used to graft bone defects 
encountered in treatment of humerus, radius, femur, tibia, calcaneus, vertebra, and odontoid 
factures (Table 5), as well as bone defect encountered during knee or hip revision surgery and 
treatment of endochondrale bone cysts. 
BoneSource® was subjected to one multicenter prospective randomized trial17. 
Metaphyseal bone defects of thirty-eight fractures, including femur, tibia, calcaneus, humerus, 
and distal radius fractures were grafted with either BoneSource® or autologous bone. 
Adequate reduction was maintained in 83 % of the defects treated with BoneSource® versus 
67 % of the defect treated with autologous bone. Furthermore, reduction and injection of 
BoneSource® was compared with reduction and fixation with K-wires as a treatment for 
displaced distal radius fractures18. In their study, all clinical and radiographic parameters were 
worse after twenty-six weeks in the BoneSource® groups, and they concluded that 
BoneSource® alone does not provide sufficient fixation after reduction of displaced radial 
fractures. 
Calcibon® is mostly used for grafting defects resulting of (osteoporotic) vertebral 
fractures. One prospective trial19, several prospective20-22 and retrospective23 case-series all 
8 
 
 
 
indicate that grafting with Calcibon® gives comparable results to using 
polymethylmethacrylaat (PMMA). 
Norian SRS® is described in more than twenty manuscripts and has been used as a 
bone graft for filling bone voids resulting of fractures of the proximal humerus, distal radius, 
proximal femur, proximal tibia, or calcaneus, as well as in odontoid fractures. Keating et al. 
treated 49 lateral tibia plateau fractures with internal fixation and Norian SRS®. After one 
year, 95 % had good or excellent Rasmussen knee scores but also 20 % showed radiological 
evidence of post-traumatic osteoarthritis24. In a randomized controlled trial including 323 
patients, percutaneous injection of Norian SRS® after closed reduction of displaced distal 
radius fractures resulted in accelerated rehabilitation and improved clinical outcomes after 
two years compared with reduction only25. Norian SRS® was used for grafting defects 
resulting from calcaneal fractures and it allowed full weight bearing as early as three weeks 
after open reduction and internal fixation26. Furthermore, the use of Norian SRS® has used in 
acetabular cup revision surgery (case-report27), knee replacement surgery (case-series28). One 
study that was designed to treat enchondromas with Norian SRS® was stopped because three 
of the four included patients had severe pain after curettage of enchondroma and subsequent 
grafting with Norian SRS® 29. 
ChronOSTM Inject is indicated for use in femur, tibia, calcaneus, humerus, and radius 
fractures by the manufacturer, however there were no clinical studies found that describe the 
use of ChronOSTM Inject in this indication (Table 5). ChonOSTM Inject has been used to treat 
benign bone cysts in children. After treating twenty-four pediatric patients, ChonOSTM Inject 
was found to be safe and therefore could provide an alternative treatment for benign bone 
cysts in children30.  
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Discussion 
 
Commercially available CPCs have different mechanical, structural and biological properties. 
Mechanical, structural and biological properties are mainly explained by their chemical 
composition. Based on chemical composition, CPCs can be classified into apatite-forming 
and brushite-forming CPCs. This classification may prove helpful in selection of CPCs for 
bone defects at specific fracture sites. In general, apatite-forming CPCs offer more 
mechanical strength and have a low resorption rate. Brushite-forming CPCs, on the other 
hand, offer only limited mechanical strength and have a high resorption rate.  
Bone graft materials should offer mechanical support to surrounding bone and soft 
tissues in order to facilitate fracture healing. Apatite-forming CPCs have compression 
strengths in the range of trabecular bone (Table 3), and may therefore be most suitable to graft 
defects of metaphyseal bone defect. Brushite-forming CPCs only offer minimal mechanical 
strength, and they should therefore only be used in situations in which sufficient mechanical 
stability can already be acquired using fixation hardware. Overall, CPCs do not possess 
sufficient mechanical strength to be used in cortical or weight-bearing bone defect. 
 Micro-CT data indicates that CPCs form a rather dense structure with only a limited 
amount of pores that may allow bone and vessel ingrowth. The working mechanism in which 
CPCs can support bone formation is therefore more likely based on gradual resorption of the 
CPC and subsequent bone formation. Resorption of CPCs is an active process mediated by 
osteoclasts7. The resorption rate is an interplay of chemical composition, structure and volume 
of the CPC and the availability and activity of osteoclasts. Resorption of CPC should be 
followed by bone formation until complete regeneration of the bone defects has occurred. The 
regenerative potential of the surrounding bone should therefore be taken into account, and 
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when rapid bone formation can be expected, fast resorbing brushite-forming CPCs, such as 
ChronOSTM Inject, may be preferred over apatite-forming CPCs. 
CPCs are mostly studied as a bone substitute material to graft metaphyseal bone 
defects (Table 5). Grafted metaphyseal bone defects include fractures of the femur, tibia, 
calcaneus, humerus, radius, and vertebra. The majority of the studies included in the 
systematic literature search consist of case-series. Case-series can provide relevant knowledge 
about the specific indication in which a CPC can be used and the relative safety, however they 
are not the preferred evidence to draw well-founded conclusions on the clinical benefits of 
using CPCs. Furthermore, the average number of clinical studies performed with each CPC 
product is surprisingly low, especially for BoneSource®, ChronOSTM Inject and Calcibon® 
(Table 4). More clinical studies, preferably randomized controlled trials, are therefore desired 
and can contribute to better understanding of the potential indications and benefits of different 
CPC products.  
 
Limitations 
There are limitations to this work. Firstly, the selection of CPC products was based upon their 
availability for use in trauma and orthopaedic surgery in the Netherlands. The included 
products are widely available and used worldwide, which supports a wide relevance of this 
paper. On the other side, several other CPC products such as Norian Drillable®, HydroSet®, 
alpha-BSM® and Callos® were not included. Furthermore, biological properties were studied 
in a tibia drill-hole defect model. This model has the advantage over other models that it 
allows for evaluation of multiple CPCs within one animal. This makes direct comparison of 
the studied CPCs more relevant. On the other hand, it model might be a clinically less 
relevant, since CPC products are predominantly used to graft metaphyseal bone defects. 
Therefore, whether metaphyseal bone defects can successfully be grafted with the studied 
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CPC cannot be directly translated from their performance in this model. The biological 
properties as described here provide important clues that can help to determine which product 
is most suitable for each type of bone defect encountered during clinical practice. Finally, the 
systematic literature search may not have been able to retrieve all relevant publications of the 
included CPC products. This risk is minimized through performing the search with the 
product name as search term in two different databases (Embase and PubMed) and screening 
reference lists of the included articles for additional publications (one publication found). 
Missing publications that did not specify the product name is not considered a limitation, 
since this systematic search was conducted to provide insight into the available clinical 
evidence of the commercially available CPC products, helping trauma and orthopaedic 
surgeons to select the most suitable product. Mentioning the product name was therefore 
essential for this study. 
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Figure captions 
 
Figure 1: Filling capability of CPCs in a drill-hole defect 
Mirco-CT and corresponding Goldner’s trichrome histological images. S, substitute material; 
B, bone. Bar indicates 1 mm. 
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Figure 2: CPC integration and bone forming activity at the CPC-interface 
Goldner’s trichrome histological images of the CPC-interface and corresponding 
fluorochrome images. S, substitute material; B, bone. Red label is tetracycline and green label 
is calcein green. Bar indicates 1 mm. 
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Supplementary Materials and Methods 
 
Animal experiment 
In five skeletally mature female milk goats, each weighing 50-60kg, a drill-hole bone defect 
model was used in which three holes were created at the diaphysis of the right tibia. Two of 
the holes were grafted with a CPC and one was left empty, serving as a control. All products 
were tested in duplicate and randomized over the proximal, distal and middle holes. After 
three months, the goats were killed and the grafted bone defects were analyzed using micro-
CT, histology, and fluorochrome labeling. 
 
Surgical procedure 
The operation was performed under general anesthesia induced by an intravenous injection of 
0.3ml medetomidine (1mg/ml) followed by 20ml propofol (10mg/ml) and maintained by 
isoflurane 1.5% through a constant volume ventilator, administered through an endotracheal 
tube. The goats received prophylactic antibiotics according to the following scheme: 12.5ml 
amoxicillin (48mg/ml) at the start of the operation and 7.5ml ampicillin (100mg/ml) during 
the operation; and two and four days after the operation. 
Before surgery, the animal was immobilized on its right side and the right limb was 
shaved, washed, and disinfected with povidone-iodine. A longitudinal incision was made on 
the medial surface of the tibia, and the bone was exposed by blunt dissection. Three 
unicortical 2.0mm diameter holes were drilled at low rotational drill speeds and continuous 
cooling with cold physiologic saline, with an interspace of 2.5cm. The 2.0mm diameter holes 
were enlarged to 5.0mm diameter and irrigated and packed with sterile cotton gauze, and the 
calcium phosphate cements were then prepared. Subsequently, the cements were injected into 
the bone defects and allowed to solidify. Any extruding material was removed. The soft 
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tissues and skin were closed in separate layers with Vicryl sutures. Post operative analgesia 
consisted of 0.8ml buprenorphine (300μg/ml) and 1.0ml flunixin (50mg/ml) on day zero to 
three post surgery. 
 
Fluorochrome labeling 
The fluorochrome labels were administered intravenously at 14 days (tetracycline 
hydrochloride, 30 mg/kg (Sigma)) and four days (calcein, 10 mg/kg intravenously (Sigma)) 
before they were killed using an overdose pentobarbital. 
 
Micro-CT evaluation 
The right tibias were taken out and trimmed to a suitable size for micro-CT scanning. A 9 
µm-resolution protocol (75 kV energy, 133 µA current, 1.0 mm Al filter) was used with a 
SkyScan 1076 micro-CT scanner (Bruker micro-CT N.V., Kontich, Belgium). The CT images 
were reconstructed using NRecon software version 1.5 (Bruker micro-CT N.V., Kontich, 
Belgium). 
 
Histological evaluation 
After micro-CT scanning, each tibia was trimmed to a size suitable for histological 
processing. Subsequently, all specimens were fixed in paraformaldehyde (4%) overnight, 
dehydrated in a graded series of ethanol, and embedded in methylmethacrylate (MMA). After 
polymerization, undecalcified thin (6μm) sections were made with a heavy duty microtome in 
a transverse direction through the middle of the defect area. Sections were stained using 
Goldner’s trichrome and evaluated with a light microscope (Olympus BX50). Fluorochrome 
labels were evaluated in unstained sections using an epifluorescence microscope (Axiovert 
200MOT/Carl Zeiss) equipped with a double filter block. 
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Table 1. Product specifications 
 
Product Manufacturer Available volumes 
BoneSource® Stryker 1.5 cc, 3 cc, 6 cc, 15cc, 30cc 
Calcibon® Biomet 4 cc, 8 cc, 16 cc 
ChronOSTM Inject DePuy Synthes 2.5 cc, 5 cc, 10 cc 
Norian SRS® DePuy Synthes 3 cc, 5 cc, 10 cc 
 
 
Table 2. Chemical composition and mixing properties 
 
Product Chemical composition Mixing 
time 
Final 
setting 
time 
Final 
setting 
product
7 
BoneSource® 80% TCP / 20% HA 2-4 m 5-10 m apatite 
Calcibon® 62.5% α-TCP / 26.8% DCPA / 8.9% 
CaCO3 / 1.8% HA 
1 m 5 m apatite 
ChronOSTM Inject 73% β-TCP / 21% MCP.H2O / 5% 
MHPT 
1 m 11 m brushite 
Norian SRS® α-TCP / CaCO3 / MCP.H2O 1 m 15 m apatite 
 
CaCO3, calcium carbonate; DCPA, dicalcium phosphate anhydrous; HA, hydroxyapatite; 
MCP.H2O, monocalcium phosphate monohydrate; MHPT, magnesium hydrogen phosphate 
trihydrate; TCP, tricalcium phosphate. 
 
 
Table 3. Structural and mechanical properties  
 
 
Product Porosity 
(%)13 
Compression 
strength (MPa)13 
BoneSource® 0.4 14 
Calcibon® 0.9 34 
ChronOSTM Inject 4.5 1 
Norian SRS® 0.3 26 
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Table 4: Number of publications retrieved during the systematic literature search 
 
 
Products Inclusion Exclusion  Final 
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Apatite-CPC  
BoneSource® 23 9 1 11 1 1 1 
Calcibon® 5 1 0 0 0 0 4 
Norian SRS® 48 9 0 6 6 0 27 
Brushite-CPC  
ChronOSTM Inject 2 1 0 0 0 0 1 
 
 
 
Table 5: Clinical evidence for CPC use in fracture surgery 
 
 
Products Fracture 
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Apatite-CPC  
BoneSource® IV17 IV 17, 18 IV 17 IV 17 IV 17 N.D. N.D. 
Calcibon® N.D. x N.D. x x II19, 20, 22, 23 N.D. 
Norian SRS® V31, 32 II25, 33-43 II44-47 V48-51 V26, 52, 53 N.D. VI 54 
Brushite-CPC  
ChronOSTM Inject x x x x x N.D. N.D. 
 
I–VI, the highest clinical level of evidence according to Mahid et al. 55 supporting the use for 
specific indication; x, indicated by manufacturer only; N.D., no data available. 
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